Preclinical validation of PB002, a novel bacterial mix for the treatment of ulcerative colitis

• Unité de recherche: INNOSUISSE
• Numéro de projet: 40713.1 IP-LS
• Titre du projet anglais: Preclinical validation of PB002, a novel bacterial mix for the treatment of ulcerative colitis

Description succincte (Allemand)

Preclinical validation of PB002, a novel bacterial mix for the treatment of ulcerative colitis

Description succincte (Anglais)

Preclinical validation of PB002, a novel bacterial mix for the treatment of ulcerative colitis

Résumé des résultats (Abstract) (Allemand)

PharmaBiome is pioneering the development of next-generation microbiome therapies. To bridge the gap from proof of concept to the clinic we will validate the worldwide first co-cultivated microbiome product in relevant animal models of colitis as part of the preclinical studies.

Résumé des résultats (Abstract) (Anglais)